|
Valoración DCF de GT BioPharma, Inc. (GTBP)
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
GT Biopharma, Inc. (GTBP) Bundle
¡Simplifique la valoración de GT BioPharma, Inc. (GTBP) con esta calculadora DCF personalizable! Con Real GT BioPharma, Inc. (GTBP) financieras y entradas de pronóstico ajustable, puede probar escenarios y descubrir el valor razonable de GT BioPharma, Inc. (GTBP) en minutos.
Discounted Cash Flow (DCF) - (USD MM)
Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITDA | -11.5 | -25.0 | .0 | .0 | 6.0 | .0 | .0 | .0 | .0 | .0 |
EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Depreciation | .0 | .0 | 57.5 | 21.3 | 13.6 | .0 | .0 | .0 | .0 | .0 |
Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
EBIT | -11.5 | -25.0 | -57.5 | -21.3 | -7.6 | .0 | .0 | .0 | .0 | .0 |
EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Total Cash | .0 | 5.3 | 32.0 | 16.5 | 14.0 | .0 | .0 | .0 | .0 | .0 |
Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Accounts Payable | 1.9 | 2.2 | 8.2 | 3.1 | 4.3 | .0 | .0 | .0 | .0 | .0 |
Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EBITAT | -12.1 | -27.9 | -58.2 | -20.9 | -7.6 | .0 | .0 | .0 | .0 | .0 |
Depreciation | ||||||||||
Changes in Account Receivables | ||||||||||
Changes in Inventories | ||||||||||
Changes in Accounts Payable | ||||||||||
Capital Expenditure | ||||||||||
UFCF | -10.1 | -27.6 | 5.3 | -4.7 | 7.2 | -4.3 | .0 | .0 | .0 | .0 |
WACC, % | 7.1 | 7.1 | 7.1 | 7.1 | 7.1 | 7.1 | 7.1 | 7.1 | 7.1 | 7.1 |
PV UFCF | ||||||||||
SUM PV UFCF | -4.0 | |||||||||
Long Term Growth Rate, % | 2.00 | |||||||||
Free cash flow (T + 1) | 0 | |||||||||
Terminal Value | 0 | |||||||||
Present Terminal Value | 0 | |||||||||
Enterprise Value | -4 | |||||||||
Net Debt | -1 | |||||||||
Equity Value | -3 | |||||||||
Diluted Shares Outstanding, MM | 1 | |||||||||
Equity Value Per Share | -2.24 |
What You Will Receive
- Adjustable Forecast Parameters: Seamlessly modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Comprehensive Data: GT Biopharma, Inc.'s (GTBP) financial data pre-loaded to facilitate your analysis.
- Automated DCF Calculations: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Tailored and Professional Design: A refined Excel model that meets your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive GTBP Financials: Gain access to reliable pre-loaded historical data and future forecasts.
- Tailored Forecast Assumptions: Modify highlighted cells for key metrics like WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic updates for DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Clear charts and summaries to help you visualize valuation outcomes.
- Designed for All Skill Levels: A straightforward, intuitive layout suitable for investors, CFOs, and consultants.
How It Works
- 1. Access the Template: Download and open the Excel file containing GT Biopharma, Inc. (GTBP)'s preloaded data.
- 2. Modify Assumptions: Adjust critical inputs such as growth rates, WACC, and capital expenditures.
- 3. Analyze Results Instantly: The DCF model automatically computes intrinsic value and NPV.
- 4. Explore Scenarios: Evaluate various forecasts to investigate different valuation possibilities.
- 5. Present with Assurance: Deliver professional valuation insights to enhance your decision-making.
Why Choose This Calculator for GT Biopharma, Inc. (GTBP)?
- Accuracy: Utilizes real GT Biopharma financials to ensure precise data.
- Flexibility: Tailored for users to experiment and adjust inputs as needed.
- Time-Saving: Eliminate the need to construct a DCF model from the ground up.
- Professional-Grade: Crafted with the expertise and usability expected at the CFO level.
- User-Friendly: Intuitive design makes it accessible for users without extensive financial modeling skills.
Who Should Use This Product?
- Individual Investors: Make informed decisions about buying or selling GT Biopharma, Inc. (GTBP) stock.
- Financial Analysts: Streamline valuation processes with ready-to-use financial models for GT Biopharma, Inc. (GTBP).
- Consultants: Deliver professional valuation insights on GT Biopharma, Inc. (GTBP) to clients quickly and accurately.
- Business Owners: Understand how biotech companies like GT Biopharma, Inc. (GTBP) are valued to guide your own strategy.
- Finance Students: Learn valuation techniques using real-world data and scenarios related to GT Biopharma, Inc. (GTBP).
What the Template Contains
- Pre-Filled Data: Includes GT Biopharma’s historical financials and forecasts.
- Discounted Cash Flow Model: Editable DCF valuation model with automatic calculations.
- Weighted Average Cost of Capital (WACC): A dedicated sheet for calculating WACC based on custom inputs.
- Key Financial Ratios: Analyze GT Biopharma’s profitability, efficiency, and leverage.
- Customizable Inputs: Edit revenue growth, margins, and tax rates with ease.
- Clear Dashboard: Charts and tables summarizing key valuation results.